Thymalin
Thymalinum, calf thymus polypeptide complex, thymus extract (Khavinson)
Thymalin is not a peptide in the usual sense. It is a low-molecular-weight polypeptide complex extracted from calf thymus, standardised by biological activity rather than chemical composition. It is a registered medicine in Russia and has a large Soviet and Russian clinical literature, but that literature comes almost entirely from the institute that developed it and has never been independently replicated.
Mechanism
Thymalin is not a defined molecule. It is a low-molecular-weight polypeptide complex extracted from calf thymus, described by Morozov and Khavinson in 1981 and standardised by biological assay rather than by chemical characterisation. Khavinson's group attributes its activity to short peptide fragments contained within the mixture: principally Glu-Trp (thymogen), Lys-Glu (vilon) and Glu-Asp-Pro (crystagen). The proposed pharmacology is restoration of T-lymphocyte differentiation and normalisation of the CD4/CD8 ratio in states of thymic involution or acquired immunodeficiency, with reported effects on natural killer activity and on haematopoietic stem cell differentiation.
The broader theoretical frame is the 'peptide bioregulator' hypothesis: that ultrashort peptides penetrate the cell and nucleus, bind specific promoter sequences in DNA and thereby modulate tissue-specific gene expression. That model originates from a single research school in St Petersburg and has not been established as the operative mechanism in vivo by independent structural or molecular biology groups. It should be read as a hypothesis under active advocacy, not as settled pharmacology.
One practical point deserves emphasis over any mechanistic detail. Because thymalin is an animal-tissue extract of undefined composition, its batch-to-batch consistency, the identity of its active species, and its impurity and immunogenicity profile are categorically different from those of a synthetic peptide of known sequence. Bovine-derived injectable tissue extracts also carry the general regulatory concerns that apply to any bovine material, which is one reason such preparations are not licensed in Western jurisdictions.
What the research shows
The human literature on thymalin is extensive in volume and weak in quality. The two facts must be held together. The most widely cited claim is a long-term geroprotection study in which 266 elderly people received thymalin, the pineal extract epithalamin, or both over six to eight years, with reported normalisation of cardiovascular, endocrine, immune and nervous system function, a 2.0-2.1-fold reduction in mortality with thymalin alone, 1.6-1.8-fold with epithalamin alone, and up to a 4.1-fold reduction with six years of annual combined courses (Khavinson and Morozov, Neuro Endocrinology Letters, 2003). An important correction to how this is usually presented: the 2002 Uspekhi Gerontologii paper and the 2003 Neuro Endocrinology Letters paper report the same 266-participant cohort, so they are one body of work, not two independent confirmations. These studies were designed, conducted and reported by the institute that developed the product. Randomisation, allocation concealment, blinding and outcome ascertainment are not reported to a standard that permits independent appraisal, and no independent group has replicated them. A survival benefit of this magnitude from a thymus extract would, if real, be among the more important findings in gerontology; that it has attracted no independent replication in over two decades is itself informative.
More recent work follows the same pattern. A 2022 report by Kuznik and colleagues described thymalin in severe COVID-19 in middle-aged and elderly patients. The mortality figures circulating in secondary and marketing sources are frequently misquoted; the published figures are 40.9% with standard care alone, 28.4% with tocilizumab and 20.6% with thymalin. This was a retrospective, non-randomised comparison of treatment groups, precisely the design most vulnerable to confounding by indication, where the reason a clinician chose one treatment over another is itself correlated with prognosis. A 2020 report described effects on differentiation of human haematopoietic stem cells in vitro, and further work from the same group examines how the KE and EW dipeptides within thymalin alter gene expression, mechanistic laboratory work, not clinical evidence.
What does not exist: any registered clinical trial of thymalin on ClinicalTrials.gov, any randomised double-blind placebo-controlled trial published in the international peer-reviewed literature, and any regulatory assessment by the FDA, EMA or MHRA. The mortality-reduction claims circulating in marketing material trace back to a small number of non-replicated studies from a single institute.
Evidence assessment
Limited evidence
Human data exist and are voluminous, but are almost entirely non-randomised, Russian-language, decades old, produced by the developing institute, and never independently replicated; the two most-cited geroprotection papers report the same 266-participant cohort rather than two independent studies, no trial of thymalin is registered on ClinicalTrials.gov, and no Western regulator has assessed it.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Peptides of pineal gland and thymus prolong human life Limited evidence
Reported normalisation of cardiovascular, endocrine, immune and nervous system indices, with mortality reduced 2.0-2.1-fold with thymalin, 1.6-1.8-fold with epithalamin, and up to 4.1-fold with six years of annual combined courses versus controls.
[Geroprotective effect of thymalin and epithalamin] Limited evidence
Reported 2.0-2.4-fold reduction in acute respiratory disease incidence and reduced incidence of heart disease, hypertension, osteoarthrosis and osteoporosis, with the same mortality reductions later reported in the 2003 paper.
[Morphological compound and indicators of the blood clotting system in severe COVID-19 patients of middle aged and elderly during treatment of Tocilizumab and Thymalin] Limited evidence
Reported hospital mortality of 40.9% with standard care, 28.4% with tocilizumab and 20.6% with thymalin, alongside changes in blood cell composition and coagulation markers.
Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells Preclinical only
Reported that thymalin reduced expression of the stem cell markers CD44 and CD117 by 2-3 fold and increased CD28 expression 6.8-fold, interpreted as stimulation of stem cell maturation towards T lymphocytes.
The Use of Thymalin for Immunocorrection and Molecular Aspects of Biological Activity Limited evidence
Summarises claimed clinical effects including a reported 2.0-2.4 fold reduction in acute respiratory disease incidence in elderly and senile people.
Safety
There is no adequate safety database for thymalin by modern standards. The Russian clinical literature reports it as well tolerated, but those reports lack systematic adverse event collection, defined follow-up, or independent monitoring, so 'well tolerated' here means 'no problems were written down' rather than 'problems were looked for and not found'.
Several specific concerns follow from what thymalin actually is. It is an injectable extract of bovine tissue, which raises immunogenicity and hypersensitivity considerations that a synthetic peptide does not, and which is a category of product Western regulators treat cautiously. Composition varies between batches by definition, so dose-response and reproducibility are not meaningful concepts in the way they are for a defined drug. Material bought outside a regulated pharmacy supply chain has no verified sterility, endotoxin or identity testing, and injected non-sterile material is the failure mode that actually injures people. Finally, an agent proposed to modulate T-cell differentiation has never been studied in people with autoimmune disease, transplant recipients, or those on immunosuppressive or immune-checkpoint therapy, the populations where an immune modulator would be most consequential.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | No MHRA marketing authorisation. Not a licensed medicine and not an authorised food supplement ingredient in the UK. |
| United States | Not approved by the FDA and never submitted for approval. It is not a recognised dietary ingredient and cannot lawfully be marketed as a supplement or drug; it circulates only via 'research use only' channels, which is a marketing formula rather than a regulatory status. |
| WADA (sport) | Not named on the WADA Prohibited List. However, athletes should note section S0 (unapproved substances), which prohibits any pharmacological substance not addressed by other sections and not currently approved by any governmental regulatory health authority for human therapeutic use. Thymalin's registration in Russia complicates that analysis rather than settling it; athletes should seek a formal ruling rather than assume permitted status. |
Questions
Thymalin is a low-molecular-weight polypeptide complex extracted from the thymus glands of calves. It is not a single molecule with a defined sequence. It is a mixture standardised by biological activity. Its developers attribute the effect to short peptides within the mixture, principally Glu-Trp, Lys-Glu and Glu-Asp-Pro. This matters because batch-to-batch composition is inherently variable in a way it is not for a synthetic peptide.
No. The lifespan claim traces to a single cohort of 266 elderly participants followed for six to eight years by the St Petersburg institute that developed the compound, reported in 2002 and again in 2003: two papers, one study. It was not reported to a standard that allows independent appraisal of randomisation or blinding, and no independent group anywhere has replicated it in over twenty years. A genuine survival benefit of this size would be a landmark finding in gerontology, and the absence of replication is telling.
Thymalin is a registered medicine in Russia. It has never been approved, or submitted for approval, in the US, UK or EU, and no Western regulator has assessed it. There is no trial of thymalin registered on ClinicalTrials.gov. Product sold internationally reaches consumers through 'research use only' labelling, which is a legal device permitting sale of an unapproved compound rather than any indication of quality or evidence.
Thymosin alpha-1 is a single, chemically defined 28-amino-acid synthetic peptide with published pharmacokinetics and multiple large randomised trials, including a 1,106-patient phase 3 study. Thymalin is an undefined bovine tissue extract with no pharmacokinetic data and no registered trials. They are sometimes discussed together because both derive from thymus research, but they are not comparable in either chemical definition or evidence base.